DYNAVAX TECHNOLOGIES CORP(DVAX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-09-30.

DYNAVAX TECHNOLOGIES CORP (DVAX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DVAX at 47.2/100 on a 32-signal composite quality model, placing it at rank #1,668 of 2,856 stocks — the bottom half of the AI-ranked universe. DVAX scores in the top quartile across free cash flow (81.4), earnings quality (81.3), revenue growth (75.4). Areas of concern include institutional flow (2.3) and profitability (17.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2025), DYNAVAX TECHNOLOGIES CORP reports quarterly revenue of $94.9M, net income of $26.9M, free cash flow of $32.6M. Top institutional holders of DVAX by reported 13-F value include BlackRock, Deep Track Capital, VANGUARD GROUP, based on the most recent SEC filings. DVAX trades on the Nasdaq exchange and files with the SEC under CIK 1029142. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DVAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DYNAVAX TECHNOLOGIES CORP directly from SEC EDGAR.